Insmed’s Brinsupri is the first drug specifically approved for treating non-cystic fibrosis bronchiectasis, a progressive and potentially fatal lung disorder. The drug, licensed from AstraZeneca, inhibits activation of neutrophils, white blood cells that play a role in inflammatory and immune responses.
The post Chronic Lung Disease in Medical Literature for More Than 200 Years Finally Has Its First Drug appeared first on MedCity News.
